|
Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, IHS, OS, OSG, SAMHSA
|
NIDA, NIAAA
|
The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency.
|
|
Interagency Dual Use Outreach Working Group (IDOWG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Develops strategies to educate the research community about Dual Use Research of Concern (DURC) and the DURC-related United States Government (USG) policies.
|
|
Interagency Epilepsy Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA, HRSA, OS
|
NICHD, NIA, NIMH, NINDS
|
This working group identifies potential joint initiatives related to epilepsy and helps to coordinate epilepsy-related efforts and information exchange within the NIH and across the HHS.
|
|
Interagency Group for Development of Lung Infection Models for P. aeruginosa and A.baumannii
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, CDC, FDA
|
NIAID
|
This interagency working group meets quarterly to discuss the development of various lung infection animal models.
|
|
Interagency Midazolam Product Coordination Team
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS
|
NINDS
|
A collaboration led by the Department of Health and Human Services (HHS) to facilitate activities, both research and regulatory, related to the Food and Drug Administration (FDA) approval of midazolam for use in treating nerve agent exposure.
|
|
Interagency Modeling and Analysis Group (IMAG)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA
|
NIBIB, CSR, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR
|
The Inter-agency Modeling and Analysis Group (IMAG) is comprised of program directors from over 10 government agencies in the US including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the Department of Agriculture (USDA), the National Aeronautics and Space Administration (NASA), the Department of Veterans Affairs (VA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program officers who have a shared interest in supporting modeling and analysis methods in biomedical, biological and behavioral systems. IMAG has promoted and supported a wide variety of modeling, notably the multi-scale modeling (MSM) initiative, which was originally a multi-agency funding opportunity announcement and supplemented by various IMAG agencies through other funding opportunity announcements. In 2018 IMAG held a "2018 IMAG Futures Meeting: Moving Forward with the MSM Consortium." The MSM workshop is being held in March 2019. Publications from the last FOA are available on the IMAG wiki page and a new FOA has just been issued, "Medical Simulators for Practicing Patient Care Providers Skill Acquisition, Outcomes Assessment and Technology Development (R01 Clinical Trial Not Allowed) (PA-19-065)."
|
|
Interagency Oncology Task Force Fellowship: Track 4
|
Training Initiative
|
FDA
|
NCI
|
This fellowship will provide training in cancer prevention (e.g., chemoprevention, vaccination, and early detection). Individuals will be trained in the drug, biologic, or device development and approval processes and their application to study populations (including healthy subjects) to facilitate the movement of novel approaches from the bench to the community. Combining training in public health, cancer prevention research, and research-related regulatory overview will allow individuals to develop expertise across these disciplines.
|
|
Interagency Pain Research Coordinating Committee (IPRCC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA
|
NINDS, NCCIH, NIDA, NIDCR, NINR
|
The Interagency Pain Research Coordinating Committee is an Affordable Care Act-mandated committee to coordinate pain research activities across the government.
|
|
Interagency Select Agent Review Group (ISARG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
NIAID, OD/OM/OB, OD/OSP
|
The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the National Institutes of Health Office of the Director (NIH-OD) and the Biomedical Advanced Research and Development Authority (BARDA), advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed.
|
|
Interagency Select Agent Review Group (ISARG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
OD/OSP, NIAID, OD/OM/OB
|
Advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed.
|